StockData
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Allogene Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.30−0.01 (-0.76%)

Close on Oct 19, 2026

Market cap
$427.61M
P/E (TTM)
–
Dividend yield
0.00%

Earnings

Next report expected Nov 5, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026During market hours$4.64M$-0.13–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026During market hours–$-0.18–
Q4 FY2025
Ended Dec 31, 2025
Mar 12, 2026During market hours–$-0.17–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025During market hours–$-0.19–
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025During market hours–$-0.23–
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025During market hours–––
Q4 FY2024
Ended Dec 31, 2024
Mar 13, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024During market hours–––
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Mar 14, 2024During market hours–––

Company guidance

Outlook given with results on Aug 12, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
GAAP Operating ExpensesGAAP2026$225.00MNew
operating expensenon-GAAP2026$165.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Allogene Therapeutics filed with the SEC